Utilising engineered peptides for immunotherapy
Drug Target Review
MAY 14, 2024
Which natural agonists impede the activation of intracellular DNA sensors in APCs, and what challenges do they pose? What potential therapeutic advantages do the engineered cationic polypeptides offer in the context of generating antitumour immune responses?
Let's personalize your content